The effect of treatment advances on the mortality results of breast cancer screening trials: A microsimulation model

Jeanette Birnbaum, Vijayakrishna K. Gadi, Elan Markowitz, Ruth Etzioni

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Mammography trials, which are the primary sources of evidence for screening benefit, were conducted decades ago. Whether advances in systemic therapies have rendered previously observed benefits of screening less significant is unknown. Objective: To compare the outcomes of breast cancer screening trials had they been conducted using contemporary systemic treatments with outcomes of trials conducted with previously used treatments. Design: Computer simulation model of 3 virtual screening trials with similar reductions in advanced-stage cancer cases but re-flecting treatment patterns in 1975 (prechemotherapy era), 1999, or 2015 (treatment according to receptor status). Data Sources: Meta-analyses of screening and treatment trials; study of dissemination of primary systemic treatments; SEER (Surveillance, Epidemiology, and End Results) registry. Target Population: U.S. women aged 50 to 74 years. Time Horizon: 10 and 25 years. Perspective: Population. Intervention: Mammography, chemotherapy, tamoxifen, aromatase inhibitors, and trastuzumab. Outcome Measures: Breast cancer mortality rate ratio (MRR) and absolute risk reduction (ARR) obtained by the difference in cumulative breast cancer mortality between control and screening groups. Results of Base-Case Analysis: At 10 years, screening in a 1975 trial yielded an MRR of 90% and an ARR of 5 deaths per 10 000 women. A 2015 screening trial yielded a 10-year MRR of 90% and an ARR of 3 deaths per 10 000 women. Results of Sensitivity Analysis: Greater reductions in advanced-stage disease yielded a greater screening effect, but MRRs remained similar across trials. However, ARRs were consistently lower under contemporary treatments. When contemporary treatments were available only for early-stage cases, the MRR was 88%. Limitation: Disease models simplify reality and cannot capture all breast cancer subtypes. Conclusion: Advances in systemic therapies for breast cancer have not substantively reduced the relative benefits of screening but have likely reduced the absolute benefits because of their positive effect on breast cancer survival. Primary Funding Source: University of Washington and National Cancer Institute.

Original languageEnglish (US)
Pages (from-to)236-243
Number of pages8
JournalAnnals of internal medicine
Volume164
Issue number4
DOIs
StatePublished - Feb 16 2016
Externally publishedYes

Fingerprint

Early Detection of Cancer
Breast Neoplasms
Mortality
Numbers Needed To Treat
Therapeutics
Mammography
Computer Simulation
Aromatase Inhibitors
National Cancer Institute (U.S.)
Health Services Needs and Demand
Information Storage and Retrieval
Tamoxifen
Registries
Meta-Analysis
Epidemiology
Outcome Assessment (Health Care)
Drug Therapy
Control Groups
Survival
Population

ASJC Scopus subject areas

  • Internal Medicine

Cite this

The effect of treatment advances on the mortality results of breast cancer screening trials : A microsimulation model. / Birnbaum, Jeanette; Gadi, Vijayakrishna K.; Markowitz, Elan; Etzioni, Ruth.

In: Annals of internal medicine, Vol. 164, No. 4, 16.02.2016, p. 236-243.

Research output: Contribution to journalArticle

Birnbaum, Jeanette ; Gadi, Vijayakrishna K. ; Markowitz, Elan ; Etzioni, Ruth. / The effect of treatment advances on the mortality results of breast cancer screening trials : A microsimulation model. In: Annals of internal medicine. 2016 ; Vol. 164, No. 4. pp. 236-243.
@article{8e6091e6691b41b6be384214e7354cc4,
title = "The effect of treatment advances on the mortality results of breast cancer screening trials: A microsimulation model",
abstract = "Background: Mammography trials, which are the primary sources of evidence for screening benefit, were conducted decades ago. Whether advances in systemic therapies have rendered previously observed benefits of screening less significant is unknown. Objective: To compare the outcomes of breast cancer screening trials had they been conducted using contemporary systemic treatments with outcomes of trials conducted with previously used treatments. Design: Computer simulation model of 3 virtual screening trials with similar reductions in advanced-stage cancer cases but re-flecting treatment patterns in 1975 (prechemotherapy era), 1999, or 2015 (treatment according to receptor status). Data Sources: Meta-analyses of screening and treatment trials; study of dissemination of primary systemic treatments; SEER (Surveillance, Epidemiology, and End Results) registry. Target Population: U.S. women aged 50 to 74 years. Time Horizon: 10 and 25 years. Perspective: Population. Intervention: Mammography, chemotherapy, tamoxifen, aromatase inhibitors, and trastuzumab. Outcome Measures: Breast cancer mortality rate ratio (MRR) and absolute risk reduction (ARR) obtained by the difference in cumulative breast cancer mortality between control and screening groups. Results of Base-Case Analysis: At 10 years, screening in a 1975 trial yielded an MRR of 90{\%} and an ARR of 5 deaths per 10 000 women. A 2015 screening trial yielded a 10-year MRR of 90{\%} and an ARR of 3 deaths per 10 000 women. Results of Sensitivity Analysis: Greater reductions in advanced-stage disease yielded a greater screening effect, but MRRs remained similar across trials. However, ARRs were consistently lower under contemporary treatments. When contemporary treatments were available only for early-stage cases, the MRR was 88{\%}. Limitation: Disease models simplify reality and cannot capture all breast cancer subtypes. Conclusion: Advances in systemic therapies for breast cancer have not substantively reduced the relative benefits of screening but have likely reduced the absolute benefits because of their positive effect on breast cancer survival. Primary Funding Source: University of Washington and National Cancer Institute.",
author = "Jeanette Birnbaum and Gadi, {Vijayakrishna K.} and Elan Markowitz and Ruth Etzioni",
year = "2016",
month = "2",
day = "16",
doi = "10.7326/M15-0754",
language = "English (US)",
volume = "164",
pages = "236--243",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "4",

}

TY - JOUR

T1 - The effect of treatment advances on the mortality results of breast cancer screening trials

T2 - A microsimulation model

AU - Birnbaum, Jeanette

AU - Gadi, Vijayakrishna K.

AU - Markowitz, Elan

AU - Etzioni, Ruth

PY - 2016/2/16

Y1 - 2016/2/16

N2 - Background: Mammography trials, which are the primary sources of evidence for screening benefit, were conducted decades ago. Whether advances in systemic therapies have rendered previously observed benefits of screening less significant is unknown. Objective: To compare the outcomes of breast cancer screening trials had they been conducted using contemporary systemic treatments with outcomes of trials conducted with previously used treatments. Design: Computer simulation model of 3 virtual screening trials with similar reductions in advanced-stage cancer cases but re-flecting treatment patterns in 1975 (prechemotherapy era), 1999, or 2015 (treatment according to receptor status). Data Sources: Meta-analyses of screening and treatment trials; study of dissemination of primary systemic treatments; SEER (Surveillance, Epidemiology, and End Results) registry. Target Population: U.S. women aged 50 to 74 years. Time Horizon: 10 and 25 years. Perspective: Population. Intervention: Mammography, chemotherapy, tamoxifen, aromatase inhibitors, and trastuzumab. Outcome Measures: Breast cancer mortality rate ratio (MRR) and absolute risk reduction (ARR) obtained by the difference in cumulative breast cancer mortality between control and screening groups. Results of Base-Case Analysis: At 10 years, screening in a 1975 trial yielded an MRR of 90% and an ARR of 5 deaths per 10 000 women. A 2015 screening trial yielded a 10-year MRR of 90% and an ARR of 3 deaths per 10 000 women. Results of Sensitivity Analysis: Greater reductions in advanced-stage disease yielded a greater screening effect, but MRRs remained similar across trials. However, ARRs were consistently lower under contemporary treatments. When contemporary treatments were available only for early-stage cases, the MRR was 88%. Limitation: Disease models simplify reality and cannot capture all breast cancer subtypes. Conclusion: Advances in systemic therapies for breast cancer have not substantively reduced the relative benefits of screening but have likely reduced the absolute benefits because of their positive effect on breast cancer survival. Primary Funding Source: University of Washington and National Cancer Institute.

AB - Background: Mammography trials, which are the primary sources of evidence for screening benefit, were conducted decades ago. Whether advances in systemic therapies have rendered previously observed benefits of screening less significant is unknown. Objective: To compare the outcomes of breast cancer screening trials had they been conducted using contemporary systemic treatments with outcomes of trials conducted with previously used treatments. Design: Computer simulation model of 3 virtual screening trials with similar reductions in advanced-stage cancer cases but re-flecting treatment patterns in 1975 (prechemotherapy era), 1999, or 2015 (treatment according to receptor status). Data Sources: Meta-analyses of screening and treatment trials; study of dissemination of primary systemic treatments; SEER (Surveillance, Epidemiology, and End Results) registry. Target Population: U.S. women aged 50 to 74 years. Time Horizon: 10 and 25 years. Perspective: Population. Intervention: Mammography, chemotherapy, tamoxifen, aromatase inhibitors, and trastuzumab. Outcome Measures: Breast cancer mortality rate ratio (MRR) and absolute risk reduction (ARR) obtained by the difference in cumulative breast cancer mortality between control and screening groups. Results of Base-Case Analysis: At 10 years, screening in a 1975 trial yielded an MRR of 90% and an ARR of 5 deaths per 10 000 women. A 2015 screening trial yielded a 10-year MRR of 90% and an ARR of 3 deaths per 10 000 women. Results of Sensitivity Analysis: Greater reductions in advanced-stage disease yielded a greater screening effect, but MRRs remained similar across trials. However, ARRs were consistently lower under contemporary treatments. When contemporary treatments were available only for early-stage cases, the MRR was 88%. Limitation: Disease models simplify reality and cannot capture all breast cancer subtypes. Conclusion: Advances in systemic therapies for breast cancer have not substantively reduced the relative benefits of screening but have likely reduced the absolute benefits because of their positive effect on breast cancer survival. Primary Funding Source: University of Washington and National Cancer Institute.

UR - http://www.scopus.com/inward/record.url?scp=84958794252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958794252&partnerID=8YFLogxK

U2 - 10.7326/M15-0754

DO - 10.7326/M15-0754

M3 - Article

C2 - 26756332

AN - SCOPUS:84958794252

VL - 164

SP - 236

EP - 243

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 4

ER -